Drug Trial Radar · NCT00922480
Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients
Last checked: Nov 19, 2026Latest source record: Apr 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
506
Actual
Start
Dec 2008
Primary completion
Jul 2009
Study completion Sep 2009
Sponsor
- Lead sponsor
- Boryung Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Seoul National University Hospital; The Catholic University of Korea; Kangbuk Samsung Hospital; Konkuk University Medical Center; Konyang University Hospital; Keimyung University; Korea University; Korea University Guro Hospital; Dongguk University International Hospital; Seoul National University Bundang Hospital; Samsung Medical Center; Asan Medical Center; Severance Hospital; Ajou University; Wonju Severance Christian Hospital; Yeungnam University Hospital; Yonsei University; Inha University Hospital; Chonbuk National University Hospital; Cheil General Hospital and Women's Healthcare Center; Chungnam National University; Chungbuk National University Hospital; Hanyang University
- First posted
- Jun 17, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan (BR-A-657•K) 60 mg\~120 mg in patients with mild to moderate essential hypertension.
Conditions
- Hypertension
Interventions
FimasartanDrug
Fimasartan 60 \~ 120mg/po take one tablets once a day
Losartan (Control)Drug
Losartan 50 mg \~ 100 mg/po, take one tablets once a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Diastolic Blood Pressure ChangeTime frame: baseline and 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.